FrancophonIA/ELRC3.0 huggingface dataset:
English: The Cmax of rivastigmine was approximately 60 % higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects.
Estonian: Kerge kuni mõõduka maksakahjustusega isikutel oli rivastigmiini Cmax ligikaudu 60% suurem ja rivastigmiini AUC üle kahe korra suurem kui tervetel isikutel.
English: Capsule contents Microcrystalline cellulose Hypromellose Colloidal silicon dioxide
Estonian: Mikrokristalne tselluloos Hüpromelloos Kolloidne ränidioksiid Magneesiumstearaat
English: Rivastigmine Teva 6 mg
Estonian: Rivastigmine Teva 6 mg kõvakapslid
English: Hepatobililary disorders Not known
Estonian: Maksa ja sapiteede häired Teadmata
English: According to its metabolism, metabolic interactions with other medicinal products appear unlikely, although rivastigmine may inhibit the butyrylcholinesterase mediated metabolism of other substances.
Estonian: Rivastigmiini metabolismi arvestades ei ole metaboolsed koostoimed teiste ravimpreparaatidega tõenäolised.
English: Adjusted treatment difference n/a p-value versus placebo ITT - LOCF population (n=287)
Estonian: Keskmine muutus 24. nädalal ± SH Kohandatud ravierinevus n/a p-väärtus vs platseebo ITT - LOCF
English: WHAT RIVASTIGMINE TEVA IS AND WHAT IT IS USED FOR The active substance of Rivastigmine Teva is rivastigmine Rivastigmine belongs to a class of substances called cholinesterase inhibitors.
Estonian: MIS RAVIM ON RIVASTIGMINE TEVA JA MILLEKS SEDA KASUTATAKSE Rivastigmine Teva's sisalduv toimeaine on rivastigmiin.
English: Subsequent increases to 4.5 mg and then 6 mg twice a day should also be based on good tolerability of the current dose and may be considered after a minimum of two weeks of treatment at that dose level.
Estonian: Edasised annuste suurendamised 4,5 mg ja seejärel 6 mg-ni kaks korda ööpäevas eeldavad samuti viimati kasutatud annuse head talumist.
English: Rivastigmine Teva 3 mg
Estonian: Rivastigmine Teva 3 mg kõvakapslid
English: Fits (seizures)
Estonian: • hood (krambid)
English: You may become dehydrated (losing too much fluid) if vomiting or diarhoea are prolonged.
Estonian: Kui oksendamine ja kõhulahtisus kestavad pikka aega, võib teil tekkida dehüdratsioon (kaotate liiga palju vedelikku).
English: Rivastigmine Teva 4.5 mg
Estonian: Rivastigmine Teva 4,5 mg kõvakapslid
English: Worsening (including bradykinesia, dyskinesia, gait abnormality) and an increased incidence or severity of tremor have been observed in patients with dementia associated with Parkinson's disease (see section 4.8).
Estonian: Parkinson'i tõvega kaasneva dementsusega patsientidel on täheldatud seisundi halvenemist (kaasa arvatud bradükineesia, düskineesia, kõndimishäired) ja treemori sagenemist ning intensiivistumist (vt lõik 4.8).
English: Rivastigmine Teva 3 mg hard capsules contains 3 mg rivastigmine as rivastigmine hydrogen tartrate Rivastigmine Teva 4.5 mg hard capsules contains 4.5 mg rivastigmine as rivastigmine hydrogen tartrate
Estonian: Rivastigmine Teva 1,5 mg kõvakapslid sisaldavad 1,5 mg rivastigmiini rivastigmiinvesiniktartraadina Rivastigmine Teva 3 mg kõvakapslid sisaldavad 3 mg rivastigmiini rivastigmiinvesiniktartraadina Rivastigmine Teva 4,5 mg kõvakapslid sisaldavad 4,5 mg rivastigmiini rivastigmiinvesiniktartraadina Rivastigmine Teva 6 mg kõvakapslid sisaldavad 6 mg rivastigmiini rivastigmiinvesiniktartraadina
English: Initial dose: 1.5 mg twice a day.
Estonian: Algannus: 1,5 mg kaks korda ööpäevas.
English: The highest dose that should be taken is 6.0 mg twice a day.
Estonian: • Kõrgeim ööpäevane annus on 6 mg, mis tuleb võtta kaks korda päevas.
English: Tel: +(44) 1323 501 111
Estonian: United Kingdom Teva UK Limited Tel: +(44) 1323 501 111
English: Subjects with hepatic impairment:
Estonian: Neerukahjustusega isikud:
English: Rivastigmine Teva 1.5 mg hard capsules
Estonian: Rivastigmine Teva 1,5 mg kõvakapslid
English: - If you have gastrointestinal reactions such as feeling sick (nausea) and being sick (vomiting) and diarrhoea.
Estonian: - kui teil esinevad seedetrakti häired nagu halb enesetunne (iiveldus), haiglane olek
English: Hard capsule Orange cap imprinted with “R” & flesh color body imprinted with “6”
Estonian: Oranž kaas, millele on trükitud “R” ja kollakasroosat värvi keha, millele on trükitud “6”
English: Magnesium stearate
Estonian: Ebanormaalne kõnnak
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 1.5 mg
Estonian: TOIMEAINE(TE) SISALDUS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 1,5 mg rivastigmiinile
English: Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Estonian: Kerge kuni keskmise raskusega Alzheimer'i tõve sümptomaatiline ravi.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 4.5 mg
Estonian: TOIMEAINE(TE) SISALDUS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 4,5 mg rivastigmiinile
English: Abdominal pain and dyspesia
Estonian: Kõhuvalu ja düspepsia
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 6 mg
Estonian: TOIMEAINE(TE) SISALDUS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 6 mg rivastigmiinile
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Tablet container - Self-adhesive, paper label - Rivastigmine Teva 1.5 mg hard capsules
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Tabletipurk - Isekleepuv pabersilt - Rivastigmine Teva 1,5 mg kõvakapslid
English: Very common • Trembling
Estonian: Väga sage • värinad
English: Rivastigmine
Estonian: Eritumine
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Tablet Container - Self-adhesive, paper label - Rivastigmine Teva 4.5 mg hard capsules
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Tabletipurk - Isekleepuv pabersilt - Rivastigmine Teva 4,5 mg kõvakapslid
English: - if you have, or have ever had, impaired kidney function.
Estonian: - kui teil on või on kunagi olnud neerutalitluse langus.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton - Rivastigmine Teva 1.5 mg hard capsules
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp - Rivastigmine Teva 1,5 mg kõvakapslid
English: Blisters
Estonian: Pearinglus
English: Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Estonian: Idiopaatilise Parkinson'i tõvega kaasneva kerge kuni keskmise raskusega dementsuse sümptomaatiline ravi.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Tablet container - Self-adhesive, paper label - Rivastigmine Teva 6 mg hard capsules
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Tabletipurk - Isekleepuv pabersilt - Rivastigmine Teva 6 mg kõvakapslid
English: Subjects with renal impairment:
Estonian: Maksakahjustusega isikud:
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 1.5 mg hard capsules
Estonian: RAVIMPREPARAADI NIMETUS Rivastigmine Teva 1,5 mg kõvakapslid
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 3 mg
Estonian: TOIMEAINE(TE) SISALDUS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 3 mg rivastigmiinile
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton - Rivastigmine Teva 6 mg hard capsules
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp - Rivastigmine Teva 6 mg kõvakapslid
English: Or:
Estonian: Eakad:
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 4.5 mg hard capsules
Estonian: RAVIMPREPARAADI NIMETUS Rivastigmine Teva 4,5 mg kõvakapslid
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 4.5 mg hard capsules Rivastigmine
Estonian: RAVIMPREPARAADI NIMETUS Rivastigmine Teva 4,5 mg kõvakapslid Rivastigminum
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Tablet container - Self-adhesive, paper label - Rivastigmine Teva 3 mg hard capsules
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Tabletipurk - Isekleepuv pabersilt - Rivastigmine Teva 3 mg kõvakapslid
English: No untoward effects on cardiac conduction were observed following concomitant administration of digoxin and rivastigmine.
Estonian: Digoksiini ja rivastigmiini samaaegsel manustamisel ei täheldatud kahjustavat toimet südame juhtesüsteemi.
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 6 mg hard capsules
Estonian: RAVIMPREPARAADI NIMETUS Rivastigmine Teva 6 mg kõvakapslid
English: Flesh colour cap imprinted with “R” & flesh color body imprinted with “3”
Estonian: Kollakasroosat värvi kaas, millele on trükitud “R” ja kollakasroosat värvi keha, millele on trükitud “3”
English: Adjusted treatment difference n/a p-value versus placebo
Estonian: Keskmine muutus 24. nädalal ± SH Kohandatud ravierinevus n/a p-väärtus vs platseebo
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton - Rivastigmine Teva 4.5 mg hard capsules
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp - Rivastigmine Teva 4,5 mg kõvakapslid
English: • Difficulty in sleeping
Estonian: • raske segasusseisund
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton - Rivastigmine Teva 3 mg hard capsules
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp - Rivastigmine Teva 3 mg kõvakapslid
English: Your doctor will tell you whether your illness allows you to drive vehicles and use machines safely.. Rivastigmine Teva may cause dizziness and somnolence, mainly at the start of treatment or when increasing the dose.If you feel dizzy or sleepy do not drive, use machines or perform any tasks that require your attention.
Estonian: Arst ütleb teile, kas teie haigus võimaldab teil ohutult autot juhtida ja masinatega töötada.
English: - if you have, or have ever had, an active stomach ulcer.
Estonian: - kui teil on või on kunagi olnudaktiivne maohaavand.
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 1.5 mg hard capsules Rivastigmine
Estonian: RAVIMPREPARAADI NIMETUS Rivastigmine Teva 1,5 mg kõvakapslid Rivastigminum
English: Cardiac disorders Common
Estonian: Südame häired Harv
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 1.5 mg For a full list of excipients, see section 6.1.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 1,5 mg rivastigmiinile.
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 3 mg hard capsules Rivastigmine
Estonian: RAVIMPREPARAADI NIMETUS Rivastigmine Teva 3 mg kõvakapslid Rivastigminum
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 3 mg hard capsules
Estonian: RAVIMPREPARAADI NIMETUS Rivastigmine Teva 3 mg kõvakapslid
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 6 mg hard capsules Rivastigmine
Estonian: RAVIMPREPARAADI NIMETUS Rivastigmine Teva 6 mg kõvakapslid Rivastigminum
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 4.5 mg For a full list of excipients, see section 6.1.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 4,5 mg rivastigmiinile.
English: Anxiety
Estonian: Agitatsioon
English: Capsule shell Red iron oxide (E172) Yellow iron oxide (E172)
Estonian: Kollane raudoksiid (E172)
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 6 mg For a full list of excipients, see section 6.1.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 6 mg rivastigmiinile.
English: Gastrointestinal haemorrhage
Estonian: Lihas-skeleti jäikus
English: Teva Nederland B.V. Tel: +31 (0) 800 0228400
Estonian: Teva Pharmaceuticals Ireland Tel: +353 (0)42 9395 892
English: Suomi/Finland ratiopharm Oy
Estonian: België/Belgique/Belgien
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 3 mg For a full list of excipients, see section 6.1.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 3 mg rivastigmiinile.
English: BATCH NUMBER BN
Estonian: PARTII NUMBER Partii nr:
English: - HDPE tablet container with a polypropylene cap and induction seal: 250 capsules
Estonian: RAVIMVORM JA PAKENDI SUURUS 250 kõvakapslit
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister - Rivastigmine Teva 4.5 mg hard capsules
Estonian: Blister - Rivastigmine Teva 4,5 mg kõvakapslid
English: Treatment
Estonian: Raviannuse määramine
English: Subjects with hepatic impairment
Estonian: • südame rütmihäired
English: Sutent sunitinib
Estonian: Sutent sunitiniib
English: What measures are being taken to ensure the safe and effective use of Sutent?
Estonian: Mis meetmed võetakse, et tagada Sutenti ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Sutent is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Sutenti võimalikult ohutu kasutamine.
English: The full EPAR for Sutent can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Sutenti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is available as capsules (12.5 mg, 25 mg, 37.5 mg and 50 mg).
Estonian: Ravimit turustatakse kapslitena (12,5 mg, 25 mg, 37,5 mg ja 50 mg).
English: This dose may also be adjusted.
Estonian: Annust võib olla vaja kohandada.
English: The European Commission granted a conditional marketing authorisation valid throughout the European Union for Sutent on 19 July 2006.
Estonian: Euroopa Komisjon andis Sutenti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. juulil 2006.
English: This was switched to a full marketing authorisation on 11 January 2007.
Estonian: Tingimuslik müügiluba muudeti tavaliseks müügiloaks 11. jaanuaril 2007.
English: The most common side effects with Sutent (seen in more than 1 in 10 patients) include fatigue (tiredness), gastrointestinal disorders (such as diarrhoea, feeling sick, inflammation of the lining of the mouth, indigestion and vomiting), respiratory (such as shortness of breath and cough) and skin disorders (such as skin discoloration, dryness of the skin and rash), hair color changes, dysgeusia (taste disturbances), epistaxis (nosebleeds), loss of appetite, hypertension (high blood pressure), palmar-plantar erythrodysaesthesia syndrome (rash and numbness on the palms and soles), hypothyroidism (an underactive thyroid gland), insomnia (difficulty falling and staying asleep), dizziness, headache, arthralgia (joint pain), neutropenia (low levels of neutrophils, a type of white blood cell), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), and leucopenia (low white blood cell counts).
Estonian: Sutenti kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on väsimus, seedetrakti häired (nagu kõhulahtisus, iiveldus, suu limaskesta põletik, seedehäired ja oksendamine), hingamishäired (nt raskendatud hingamine ja köha) ja nahahäired (nt nahavärvuse muutus, nahakuivus ja lööve), juuksevärvuse muutus, düsgeusia (maitsehäired), epistaksis (ninaverejooks), isutus, hüpertensioon (kõrgvererõhutõbi), palmaar-plantaarne erütrodüsesteesia (käe- ja jalalabade lööve ja tuimus), hüpotüroidism (kilpnäärme alatalitlus), unetus (uinumis- ja unehäired), peapööritus, peavalu, liigesevalu, neutropeenia (teatud valgeliblede neutrofiilide vähesus), trombotsütopeenia (vereliistakute vähesus), aneemia (erütrotsüütide ehk vere punaliblede vähesus) ja leukopeenia (leukotsüütide ehk vere valgeliblede vähesus).
English: Other information about Sutent
Estonian: Muu teave Sutenti kohta
English: Sutent is used if the disease is getting worse and the tumour cells are well-differentiated (similar to normal cells in the pancreas).
Estonian: Sutenti kasutatakse, kui haigus süveneb ja kasvajarakud on hästi diferentseerunud (sarnanevad kõhunäärme normaalsete rakkudega).
English: This is a summary of the European public assessment report (EPAR) for Sutent.
Estonian: See on ravimi Sutent Euroopa avaliku hindamisaruande kokkuvõte.
English: The CHMP decided that Sutent's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Sutenti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: For more information about treatment with Sutent, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Sutentiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Sutent is a medicine that contains the active substance sunitinib.
Estonian: Sutent on ravim, mis sisaldab toimeainena sunitiniibi.
English: Why has Sutent been approved?
Estonian: Miks Sutent heaks kiideti?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Sutent, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Sutenti omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The dose can be adjusted according to the patient's response to the treatment, but should be kept within the range of 25 to 75 mg. For pancreatic neuroendocrine tumours, Sutent is given at a dose of 37.5 mg once a day without a rest period.
Estonian: Patsiendi ravivastuse järgi tohib annust kohandada , kuid see peab olema vahemikus 25-75 mg. Pankrease neuroendokriintuumorite korral antakse Sutenti annuses 37,5 mg üks kord ööpäevas ilma pausita.
English: Sutent was also compared with another cancer medicine, interferon alfa, in 750 patients with metastatic renal cell carcinoma whose cancer had not been treated before.
Estonian: Sutenti võrreldi ka vähiravimi alfainterferooniga uuringus, milles osales 750 metastaatilise neerurakk-kartsinoomiga patsienti, kelle vähki ei olnud varem ravitud.
English: Sutent is used to treat adults with the following types of cancer:
Estonian: Sutenti kasutatakse täiskasvanud patsientidel järgmiste vähivormide raviks:
English: For the full list of all side effects and restrictions with Sutent, see the package leaflet.
Estonian: Sutenti kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sutent.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The main measure of effectiveness in all of the studies was how long the patients lived without their tumours getting worse.
Estonian: Kõigis uuringutes oli efektiivsuse põhinäitaja aeg haiguse süvenemiseni.
English: Sutent was compared with placebo (a dummy treatment) in 312 patients with GIST whose previous treatment with imatinib had failed and in 171 patients with worsening pancreatic neuroendocrine tumours that could not be removed with surgery.
Estonian: Sutenti võrreldi platseeboga (näiv ravim) 312 gastrointestinaalse stromaaltuumoriga patsiendil, kelle varasem ravi imatiniibiga oli ebaõnnestunud, ja 171 pankrease kaugelearenenud neuroendokriintuumoriga patsiendil, mida ei olnud võimalik kirurgiliselt eemaldada.
English: For GIST and metastatic renal cell carcinoma, Sutent is given in six-week cycles, at a dose of 50 mg once a day for four weeks, followed by a two-week ‘rest period'.
Estonian: Gastrointestinaalse stromaaltuumori ja metastaatilise neerurakk-kartsinoomi korral antakse Sutenti 6nädalaste tsüklitena: 50 mg ööpäevase annusena nelja nädala jooksul, millele järgneb kahenädalane paus.
English: The most serious side effects reported with Sutent include heart and kidney failure, pulmonary embolism (clot in a blood vessel supplying the lungs), gastrointestinal perforation (holes in the wall of the gut), and internal haemorrhages (bleeding).
Estonian: Sutenti kõige raskemate kõrvalnähtude hulka kuuluvad südame- ja neerupuudulikkus, kopsuemboolia (trombid kopsudes), seedekulgla perforatsioonid (soolemulgustused) ja sisemised verejooksud.
English: What is the risk associated with Sutent?
Estonian: Mis riskid Sutentiga kaasnevad?
English: By blocking these enzymes, Sutent can reduce the growth and spread of the cancer and cut off the blood supply that keeps cancer cells growing.
Estonian: Neid ensüüme blokeerides takistab Sutent vähi kasvu ja levikut ning peatab vähirakkude kasvu toetava verevarustuse.
English: Sutent was originally given ‘conditional approval' because there was more evidence to come about the medicine, in particular in the treatment of renal cell carcinoma.
Estonian: Sutentile anti müügiluba esialgu tingimuslikult, sest ravimi ja eelkõige selle kasutamise kohta neerurakk-kartsinoomi ravis oodati täiendavaid andmeid.
English: What benefit has Sutent shown during the studies?
Estonian: Milles seisneb uuringute põhjal Sutenti kasulikkus?
English: • pancreatic neuroendocrine tumours (tumours of the hormone-producing cells in the pancreas) that have spread or cannot be removed with surgery.
Estonian: • pankrease neuroendokriintuumorid (kõhunäärme hormoone tekitavate rakkude kasvajad), mis on levinud organismis ka mujale või mida ei saa kirurgiliselt eemaldada.
English: These enzymes can be found in some receptors at the surface of cancer cells, where they are involved in the growth and spread of cancer cells and in the blood vessels that supply the tumours, where they are involved in the development of new blood vessels.
Estonian: Neid leidub teatud retseptorites vähirakkude pinnal, kus osalevad vähirakkude kasvus ja levikus, ning kasvajaid varustavates veresoontes, kus osalevad uute veresoonte tekkes.
English: Treatment with Sutent should be started by doctors who have experience in administering cancer medicines.
Estonian: Ravi Sutentiga peab alustama vähiravimite manustamises kogenud arst.
English: It is used after treatment with imatinib (another cancer medicine) has failed;
Estonian: Ravimit kasutatakse pärast seda, kui ravi vähiravimi imatiniibiga on ebaõnnestunud;
English: • metastatic renal cell carcinoma, a type of kidney cancer, that has spread to other parts of the body;
Estonian: • metastaatiline neerurakk-kartsinoom - teatud liiki neeruvähk, mis on levinud organismis ka mujale;
English: • gastrointestinal stromal tumour (GIST), a type of cancer of the stomach and bowel where there is uncontrolled growth of cells in the supporting tissues of these organs.
Estonian: • gastrointestinaalne stromaaltuumor (GIST) - teatud liiki mao- ja soolevähk, mille korral nende elundite tugikudede rakud hakkavad takistamatult vohama.
English: The active substance in Sutent, sunitinib, is a protein kinase inhibitor.
Estonian: Sutenti toimeaine sunitiniib on proteiinkinaasiinhibiitor ehk aine, mis blokeerib teatud ensüüme proteiinkinaase.
English: Sutent is used in patients with GISTs that cannot be removed with surgery or have spread to other parts of the body.
Estonian: Sutenti kasutatakse gastrointestinaalsete stromaaltuumoritega täiskasvanute raviks, kui neid tuumoreid ei saa kirurgiliselt eemaldada või kui vähk on levinud organismis ka mujale.
English: What is Sutent used for?
Estonian: Milleks Sutenti kasutatakse?